Blockchain Registration Transaction Record

Nutriband Secures $1.75M from Warrant Exercises to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) raises $1.75M from warrant exercises to fund AVERSA Fentanyl clinical development and FDA NDA submission. Learn more.

This news matters because the $1.75 million in proceeds provides critical funding for Nutriband to advance AVERSA Fentanyl, a potential first-in-class abuse-deterrent opioid patch, through late-stage clinical development and toward FDA submission. If approved, AVERSA Fentanyl could address the ongoing opioid crisis by reducing abuse and misuse, while also offering a significant commercial opportunity with estimated peak annual U.S. sales of $80 million to $200 million. For investors, the elimination of remaining warrants simplifies the capital structure and signals confidence in the company’s pipeline, potentially enhancing shareholder value.